Introduction {#tca12899-sec-0005}
============

Lung cancer remains the leading cause of cancer death worldwide, and non‐small cell lung cancer (NSCLC) accounts for more than 80% of lung cancer cases.[1](#tca12899-bib-0001){ref-type="ref"}, [2](#tca12899-bib-0002){ref-type="ref"} During the last decade, the identification of key driver genes in NSCLC, such as *EGFR* and *ALK*, and the promising results obtained with the use of tyrosine kinase inhibitors (TKIs) that target these driver genes to treat NSCLC have rapidly facilitated the development of targeted therapy and precision medicine.[3](#tca12899-bib-0003){ref-type="ref"}, [4](#tca12899-bib-0004){ref-type="ref"}, [5](#tca12899-bib-0005){ref-type="ref"}, [6](#tca12899-bib-0006){ref-type="ref"}, [7](#tca12899-bib-0007){ref-type="ref"}, [8](#tca12899-bib-0008){ref-type="ref"}, [9](#tca12899-bib-0009){ref-type="ref"}, [10](#tca12899-bib-0010){ref-type="ref"}, [11](#tca12899-bib-0011){ref-type="ref"}, [12](#tca12899-bib-0012){ref-type="ref"} In this era of precision medicine, molecular testing has become extremely important for both the classification and treatment of lung cancer.[13](#tca12899-bib-0013){ref-type="ref"}

ROS1 is a receptor tyrosine kinase of the insulin receptor family. It was first discovered in NSCLC in 2007.[14](#tca12899-bib-0014){ref-type="ref"} The *ROS1* fusion partners identified in lung cancer to date include *CD74*, *SLC34A2*, *GOPC*, *CCDC6*, *SDC4*, *TPM3*, *EZR*, *LRIG3*, *KDELR2*, *LIMA1*, *MSN*, *CLTC*, *TPD52L1*, *FIG*, *TMEM106B*, *FAM135B*, and *SLC6A17*, with an overall prevalence of 0.9--2.6% in NSCLC[15](#tca12899-bib-0015){ref-type="ref"}, [16](#tca12899-bib-0016){ref-type="ref"}, [17](#tca12899-bib-0017){ref-type="ref"}, [18](#tca12899-bib-0018){ref-type="ref"}, [19](#tca12899-bib-0019){ref-type="ref"}, [20](#tca12899-bib-0020){ref-type="ref"}, [21](#tca12899-bib-0021){ref-type="ref"}, [22](#tca12899-bib-0022){ref-type="ref"}, [23](#tca12899-bib-0023){ref-type="ref"}, [24](#tca12899-bib-0024){ref-type="ref"}, [25](#tca12899-bib-0025){ref-type="ref"} and up to 3% in lung adenocarcinoma,[19](#tca12899-bib-0019){ref-type="ref"}, [26](#tca12899-bib-0026){ref-type="ref"} representing a novel molecular subgroup of NSCLC. Several important clinical studies have shown that crizotinib, an *ALK* inhibitor, has high activity when treating NSCLC patients harboring *ROS1* fusion, with a response rate of 72--80%.[27](#tca12899-bib-0027){ref-type="ref"}, [28](#tca12899-bib-0028){ref-type="ref"} Based on these promising results, the American, Japanese, and Chinese authorities have approved crizotinib for the treatment of *ROS1* fusion‐positive NSCLC patients. This development has highlighted the need for thorough investigations of *ROS1* fusions in patients with NSCLC.

Similar to patients with *ALK* fusions, *ROS1* fusion‐positive patients tend to be younger, never‐smokers, with adenocarcinoma histology.[9](#tca12899-bib-0009){ref-type="ref"}, [10](#tca12899-bib-0010){ref-type="ref"}, [11](#tca12899-bib-0011){ref-type="ref"}, [21](#tca12899-bib-0021){ref-type="ref"}, [22](#tca12899-bib-0022){ref-type="ref"} However, the clinical features of patients harboring a *ROS1* fusion gene are not fully understood; the vast majority of studies have had small to modest sample sizes,[17](#tca12899-bib-0017){ref-type="ref"}, [29](#tca12899-bib-0029){ref-type="ref"}, [30](#tca12899-bib-0030){ref-type="ref"}, [31](#tca12899-bib-0031){ref-type="ref"}, [32](#tca12899-bib-0032){ref-type="ref"} which compromised the detection power of each individual study. Therefore, in this study, we performed a large‐scale, retrospective analysis to determine the prevalence and clinicopathological features of *ROS1* fusion in Chinese patients with NSCLC.

Methods {#tca12899-sec-0006}
=======

Study design {#tca12899-sec-0007}
------------

This investigation was a real‐world, retrospective, multicenter, epidemiological study of *ROS1* fusion prevalence in patients with NSCLC from 10 hospitals across China. The primary objective of the study was to assess the frequency of *ROS1* gene fusion. The secondary objective was to investigate the correlations between *ROS1* fusion status and demographic and clinical factors.

Patients {#tca12899-sec-0008}
--------

Eligible patients had pathologically confirmed NSCLC with *ROS1* fusion detection results. The following data were collected: age, gender, smoking status, pathological type and stage, and tumor node metastasis (TNM) stage. Pathological types and stages were determined according to the 2015 World Health Organization classification.[33](#tca12899-bib-0033){ref-type="ref"} The TNM stage was classified according to 7th edition of the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) TNM staging.[34](#tca12899-bib-0034){ref-type="ref"} The Institutional Review Board of Shanghai Chest Hospital approved the study. All patients provided written informed consent before enrollment.

Detection of *ROS1* fusion by quantitative real‐time PCR {#tca12899-sec-0009}
--------------------------------------------------------

Total RNAs isolated from formalin‐fixed paraffin‐embedded (FFPE) tissue from each patient were used to detect *ROS1* fusion with the quantitative real‐time (qRT)‐PCR based ADx‐ARMS ROS1 Gene Fusion Detection Kit, ADx‐ARMS ALK/ROS1 Gene Fusion Joint Detection Kit, or ADx‐ARMS EGFR/ALK/ROS1 Gene Joint Detection Kit (Amoy Diagnostics Co., Ltd., Xiamen, China), according to the manufacturer\'s instructions (Table [S1](#tca12899-supitem-0001){ref-type="supplementary-material"}). In brief, the qRT‐PCR conditions for complementary DNA were as follows: one cycle of 95 °C for 5 minutes; 15 cycles of denaturation at 95 °C for 25 seconds, annealing at 64 °C for 20 seconds, and elongation at 72 °C for 20 seconds to ensure specificity; and up to 31 cycles of 93 °C for 25 seconds, 60 °C for 35 seconds (data collection), and 72 °C for 20 seconds. An external control for each sample and an internal control for each tube were used to check the effects of DNA insufficiency or PCR inhibitors.

Statistical analyses {#tca12899-sec-0010}
--------------------

A two‐tailed Student\'s *t*‐test was used to compare the ages of the *ROS1* fusion positive and negative groups. Chi‐square or Fisher\'s exact tests were used to analyze the relationship between *ROS1* fusion and other characteristics of NSCLC, including gender, smoking status, and pathological type and stage. All statistical calculations were performed using R 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria), and *P* \< 0.05 was defined as significant with a two‐sided test. To better predict *ROS1* fusion frequency, multivariate logistic regression was performed for factors with a *P* value \< 0.05 in the univariate analysis, and the significance level was set at 1% because of the large data set.

Results {#tca12899-sec-0011}
=======

Patients {#tca12899-sec-0012}
--------

The 6066 patients eligible for this study comprised 3584 men and 2482 women, at an average age of 60.89 ± 10.60 years. The sample types for these 6066 patients were 2011 (33.15%) postoperative pathologic specimens, 181 (2.98%) cytology specimens, and 3874 (63.86%) biopsies.

Positive rate of *ROS1* fusion in non‐small cell lung cancer (NSCLC) patients {#tca12899-sec-0013}
-----------------------------------------------------------------------------

ROS1 fusions were detected in 157 of the 6066 patients with NSCLC, for a 2.59% positive rate. In the subgroup with known *EGFR* gene and *ALK* fusion status, the positive rate of *ROS1* was 4.36% (68/1559) in patients with *EGFR* wild‐type and *ALK* fusion‐negative status (Fig [1](#tca12899-fig-0001){ref-type="fig"}a).

![(a) The *ROS1* fusion positive rate among all patients and patients with wild‐type *EGFR* and *ALK* negative status. (b) Different age groups in relation to *ROS1* fusion status. (![](TCA-10-47-g003.jpg "image")) *ROS1* positive, (![](TCA-10-47-g004.jpg "image")) *ROS1* negative, and (![](TCA-10-47-g005.jpg "image")) *ROS1* positive %.](TCA-10-47-g001){#tca12899-fig-0001}

Correlation analysis of *ROS1* fusion status and characteristics in NSCLC patients {#tca12899-sec-0014}
----------------------------------------------------------------------------------

We compared age, gender, smoking history, and pathological types and stages between *ROS1* fusion positive and negative patients. *ROS1* fusion correlated significantly with age, gender, smoking history, pathological type, and N stage, as shown in Table [1](#tca12899-tbl-0001){ref-type="table"}.

###### 

Summary of *ROS1* fusion prevalence and statistical analysis of subgroups classified by clinicopathological characteristics

  Features                      All NSCLC patients                                   
  ----------------------------- -------------------- --------------- --------------- ------------------------------------------------
  Age (years, Mean ± SD)        56.09 ± 11.38        61.23 ± 10.55   61.11 ± 10.60    \<0.001[†](#tca12899-note-0002){ref-type="fn"}
  Gender (*n*, %)                                                                     \<0.001[‡](#tca12899-note-0003){ref-type="fn"}
  Female                        92 (3.71%)           2390 (96.29%)   2482            
  Male                          65 (1.81%)           3519 (98.19%)   3584            
  Smoking history (*n*, %)                                                            \<0.001[‡](#tca12899-note-0003){ref-type="fn"}
  Non‐smoker                    111 (3.33%)          3218 (96.67%)   3329            
  Smoker                        23 (1.21%)           1880 (98.79%)   1903            
  NA                            23 (2.76%)           811 (97.24%)    834             
  Pathological types (*n*, %)                                                         0.01742[‡](#tca12899-note-0003){ref-type="fn"}
  Adenocarcinoma                136 (2.77%)          4776 (97.23%)   4912            
  Squamous carcinoma            4 (0.93%)            426 (99.07%)    430             
  Others                        17 (2.35%)           707 (97.65%)    724             
  Pathological stage (*n*, %)                                                         0.6826[§](#tca12899-note-0004){ref-type="fn"}
  0                             0.00%                16 (100.00%)    16              
  I                             13 (2.19%)           580 (97.81%)    593             
  II                            6 (2.18%)            269 (97.82%)    275             
  III                           34 (3.27%)           1006 (96.73%)   1040            
  IV                            75 (2.59%)           2824 (97.41%)   2899            
  NA                            29 (2.33%)           1214 (97.67%)   1243            
  T stage (*n*, %)                                                                    0.1567[§](#tca12899-note-0004){ref-type="fn"}
  T1                            12 (3.20%)           363 (96.80%)    375             
  T2                            17 (2.66%)           623 (97.34%)    640             
  T3                            3 (1.05%)            283 (98.95%)    286             
  T4                            23 (2.04%)           1102 (97.96%)   1125            
  NA                            102 (2.80%)          3538 (97.20%)   3640            
  N stage (*n*, %)                                                                    0.0171[§](#tca12899-note-0004){ref-type="fn"}
  N0                            6 (1.31%)            451 (98.69%)    457             
  N1                            4 (1.40%)            282 (98.60%)    286             
  N2                            18 (2.07%)           853 (97.93%)    871             
  N3                            26 (3.23%)           779 (96.77%)    805             
  NA                            103 (2.82%)          3544 (97.18%)   3647            
  M stage (*n*, %)                                                                       1[‡](#tca12899-note-0003){ref-type="fn"}
  M0                            20 (2.29%)           854 (97.71%)    874             
  M1                            34 (2.29%)           1448 (97.71%)   1482            
  NA                            103 (2.78%)          3607 (97.22%)   3710            

Two‐tailed Student\'s *t*‐test.

Fisher\'s exact test.

Chi‐square test for trend.

NA, not available; NSCLC, non‐small cell lung cancer; SD, standard deviation.

There was a significant difference in age between *ROS1* fusion positive (56.09 ± 11.38 years) and negative patients (61.23 ± 10.55 years; *P* \< 0.001). The positive rate of *ROS1* fusion was higher in women (3.71%, 92/2482) than in men (1.81%, 65/3584; *P* \< 0.001) and in patients without a smoking history (3.33%, 111/3329) than in patients with a smoking history (1.21%, 23/1903) (*P* \< 0.001). The Fisher\'s exact test revealed a significant difference in *ROS1* fusion positivity among subgroups classified by pathological type (*P* \< 0.001). The positive rate of *ROS1* fusion in patients with adenocarcinoma was higher (2.77%, 136/4912) than in patients with squamous carcinoma (0.93%, 4/430).

Correlation analysis of *ROS1* fusion status with pathological stage showed no significant difference between subgroups classified by P, T, or M stage (*P* \> 0.05), whereas the *ROS1* fusion positive rate in patients increased with N stage (1.31%, 1.40%, 2.07%, and 3.23% for N0, N1, N2, and N3, respectively, *P* \< 0.05). Distant metastasis did not correlate with *ROS1* fusion status (M0 vs. M1; *P* \> 0.05).

Multivariate logistic regression (at the 5% significance level) identified age, smoking status, and N stage (all *P* \< 0.05) as independent predictive factors for *ROS1* fusion status (Table [2](#tca12899-tbl-0002){ref-type="table"}). Gender and pathology type were no longer significant when stratified by smoking status (Fig [2](#tca12899-fig-0002){ref-type="fig"}).

###### 

Multivariate logistic regression analysis for *ROS1* fusion status

  Comparison                    Variable   Regression coefficient estimate   Standard error            Odds ratio estimate (95% CI)   *P*
  ---------------------------- ----------- --------------------------------- ------------------------- ------------------------------ -----
  Smoking vs. age               Intercept  −1.1999                           0.4312                                                   
  Smoking                        −0.9195   0.2330                            0.3987 (0.2525--0.6295)   0.0001                         
  Age                            −0.0378   0.0076                            0.9629 (0.9487--0.9774)   0.0000                         
  Age vs. N stage               Intercept  −2.5851                           0.8198                                                   
  Age                            −0.0311   0.0125                            0.9693 (0.9459--0.9933)   0.0126                         
  N stage                        0.3233    0.1465                            1.3817 (1.0369--1.8412)   0.0273                         
  Smoking vs. N stage           Intercept  −4.2088                           0.3497                                                   
  Smoking                        −1.0476   0.3421                            0.3508 (0.1794--0.6859)   0.0022                         
  N stage                        0.3826    0.1467                            1.4661 (1.0998--1.9545)   0.0091                         
  Smoking vs. gender            Intercept  −3.3045                           0.1146                                                   
  Smoking                        −0.9080   0.2695                            0.4033 (0.2378--0.6840)   0.0008                         
  Gender                         −0.1972   0.2078                            0.8210 (0.5463--1.2338)   0.3426                         
  Smoking vs. pathology type    Intercept  −3.6562                           0.5932                                                   
  Smoking                        −1.0200   0.2480                            0.3606 (0.2218--0.5863)   0.0000                         
  Pathology type                 0.3115    0.5944                            1.3654 (0.4259--4.3771)   0.6003                         

CI, confidence interval; SE, standard error.

![Combined effect of gender and smoking status on the frequency of *ROS1* fusion. (![](TCA-10-47-g006.jpg "image")) Women with *ROS1* fusion positive tumors, and (![](TCA-10-47-g007.jpg "image")) Men with *ROS1* fusion positive tumors.](TCA-10-47-g002){#tca12899-fig-0002}

With increasing age, the positive rate of *ROS1* exhibited a decreasing trend. With respect to different age groups, the highest expression of *ROS1* was in the age range of 55--60 years, while the *ROS1* negative population was concentrated in the age range of 65--70 years. Therefore, patients with positive *ROS1* fusion status are younger than those with negative *ROS1* fusion status (Fig [1](#tca12899-fig-0001){ref-type="fig"}b).

Discussion {#tca12899-sec-0015}
==========

This study is the first real‐world, multicenter, retrospective study to investigate the prevalence and clinicopathological characteristics of *ROS1* fusion in Chinese patients with NSCLC. In this study, we found that the *ROS1* fusion positive rate was higher than that reported previously.[15](#tca12899-bib-0015){ref-type="ref"}, [17](#tca12899-bib-0017){ref-type="ref"}, [26](#tca12899-bib-0026){ref-type="ref"} We confirmed that *ROS1* fusion was more prevalent in younger patients, women, never‐smokers, patients with adenocarcinoma, and patients at more advanced stages (stage III--IV). Patient age, smoking status, and N stage were independent predictive factors for *ROS1* fusion status. Gender and pathology type were not significantly correlated with tumor *ROS1* fusion status when the results were stratified by smoking status.

Our study provides evidence to guide prescreening in NSCLC patients to select a more enriched population who are more likely to harbor this specific fusion. *ROS1* fusion is rare in patients with NSCLC. In 2012, Bergethon *et al*. reported that 18 of 1073 (1.67%) NSCLC tumors had a *ROS1* rearrangement, and all 18 *ROS1* positive tumors were adenocarcinomas (2.59%, 18/694).[15](#tca12899-bib-0015){ref-type="ref"} Our study showed a similar trend, with a *ROS1* fusion prevalence of 2.77% in Chinese patients with adenocarcinoma and extremely rare *ROS1* fusion positive results in patients with non‐adenocarcinoma. In our study, patients that were younger, female, without a smoking history, with adenocarcinoma, and at an advanced clinical stage were more likely to harbor a *ROS1* fusion, and such patients should be genetically tested. The recent National Comprehensive Cancer Network Guidelines for NSCLC recommend testing for *ROS1* fusion in all patients with advanced‐stage NSCLC regardless of gender, race, smoking history, or other clinical risk factors to guide patient selection for first‐line therapy with crizotinib.[35](#tca12899-bib-0035){ref-type="ref"}

Testing methodology also plays a very important role in accurately reflecting the *ROS1* fusion prevalence. In this study, *ROS1* fusions were detected with qRT‐PCR kits approved by the China Food and Drug Administration (CFDA) for clinical use. Compared to qRT‐PCR, the traditional immunohistochemistry (IHC) assay is simple, inexpensive, and is routinely conducted in pathology laboratories. However, most previous studies have revealed that the IHC assay for *ROS1* expression detection has significant false‐positive results because of aneuploidy leading to aberrant expression.[36](#tca12899-bib-0036){ref-type="ref"}, [37](#tca12899-bib-0037){ref-type="ref"}, [38](#tca12899-bib-0038){ref-type="ref"} Fluorescence in situ hybridization (FISH) can be performed even if the concrete fusion partner is unknown and has the potential to discover all *ROS1* fusions in NSCLC. In the PROFILE 1001 clinical trial, FISH was used as a standard method to detect *ROS1* rearrangement.[28](#tca12899-bib-0028){ref-type="ref"} The qRT‐PCR assay is easy to perform, highly sensitive, and relatively inexpensive. In addition, qRT‐PCR can identify concrete fusion partners, which can be confirmed by subsequent sequencing if necessary. qRT‐PCR cannot discover novel fusion partners other than the known and designed partners. In terms of data interpretation, qRT‐PCR is more objective than IHC. For the current real world study, the qRT‐PCR method was the only option to detect *ROS1* fusion as there are no CFDA‐approved ROS1 IHC or FISH assays for routine clinical practice in China.

Some previous studies have reported that NSCLC patients with *ROS1* fusion share many clinicopathological features with patients harboring *ALK* fusions.[39](#tca12899-bib-0039){ref-type="ref"}, [40](#tca12899-bib-0040){ref-type="ref"} Similar routes of pathogenesis might exist in these two subtypes of NSCLC, and this possibility is supported by both structural and functional evidence: the *ALK* and *ROS1* kinase domains share 77% sequence homology;[17](#tca12899-bib-0017){ref-type="ref"}, [40](#tca12899-bib-0040){ref-type="ref"} and *ROS1* signaling and cell viability are substantially inhibited by crizotinib, an *ALK* inhibitor, in cell lines expressing *ROS1* fusions.[15](#tca12899-bib-0015){ref-type="ref"}, [41](#tca12899-bib-0041){ref-type="ref"} Crizotinib was the first targeted agent approved by the United States Food and Drug Administration for the treatment of advanced *ROS1*‐rearranged NSCLC, based on a phase II crizotinib trial. That trial demonstrated an objective response rate of 72% and median progression‐free survival of 19.2 months in advanced *ROS1*‐rearranged NSCLC patients.[28](#tca12899-bib-0028){ref-type="ref"} The Asian OO12‐01 clinical trial, the first and largest prospective phase II trial in East Asian patients with *ROS1* positive advanced NSCLC, reported an overall response rate of 71.7% and median progression‐free survival of 15.9 months in *ROS1* fusion patients treated with crizotinib.[42](#tca12899-bib-0042){ref-type="ref"} Based on these data, the Japanese Ministry of Health, Labour and Welfare approved crizotinib for the treatment of metastatic NSCLC with *ROS1* fusion in early 2017, and the AmoyDx ROS1 Fusion Kit was approved simultaneously as the companion diagnostic reagent for crizotinib. This kit was the first officially approved *ROS1* companion diagnostic reagent in the world. Based on evidence from the OO12‐01 clinical trial, crizotinib was then approved by the CFDA as a *ROS1* TKI in late 2017. Our findings could facilitate the patient selection process for targeted therapy with *ROS1* inhibitors.

Whether *ROS1* gene alterations influence patient survival remains controversial. In our study, we found that the *ROS1* fusion positive rate was higher in patients with nodal metastasis. Jin *et al*. reported that *ROS1* fusion positive status was highly associated with micropapillary component and aerogenous spread, which has been identified as a marker of aggressive tumor biology.[43](#tca12899-bib-0043){ref-type="ref"} In addition, our study also found that distant metastasis did not correlate with *ROS1* fusion status. However, because of the limited prognostic information, we could not evaluate the clinical implications of *ROS1* rearrangement. Further study is required to evaluate the clinical significance of *ROS1* fusion.

Rare cases of double‐positive lung cancer have been reported. In 2017, two patients harboring concomitant *ROS1* and *ALK* fusions were reported in the literature.[44](#tca12899-bib-0044){ref-type="ref"}, [45](#tca12899-bib-0045){ref-type="ref"} In our study, we found only one patient with co‐occurring *ROS1* and *ALK* fusions, suggesting that the co‐occurrence is rare in Chinese NSCLC patients. Currently, there is no consensus on standard therapy for tumors with double‐positive mutations or fusions. If concurrent driver mutations are identified, molecular diagnosis should be confirmed before proceeding with targeted therapy. *ROS1* fusion was more prevalent in *EGFR* negative and *ALK* negative patients (4.36%), indicating that combined detection of *EGFR* mutations and *ALK* and *ROS1* fusions would increase patient benefits from targeted therapy. With the 15 wide use of *ROS1* inhibitors expected in the near future, 16 accurate and extensive diagnosis of *ROS1* fusions in NSCLC is essential for clinical practice.

In summary, the positive rate of *ROS1* fusion in Chinese patients with NSCLC was 2.59%, whereas in *EGFR* wild‐type and *ALK* negative patients, the positive rate of *ROS1* fusion was 4.36%. Our results showed that *ROS1* fusion was more prevalent in patients that were younger, female, without a smoking history, with adenocarcinoma, and at advanced stages. The prevalence of *ROS1* gene fusion was 2.77% in patients with adenocarcinoma and was significantly lower (0.93%) in patients with squamous carcinoma. The observed frequency of tumor *ROS1* fusion in demographic and clinical subgroups of Chinese patients suggests that *ROS1* fusion testing should be considered for all NSCLC patients with stage IIIB/IV adenocarcinoma. Such an approach will help ensure the optimal identification and treatment of patients whose tumors harbor a *ROS1* fusion.

Disclosure {#tca12899-sec-0016}
==========

No authors report any conflict of interest.

Supporting information
======================

###### 

**Table S1**. *ROS1* fusion genes detectable by the AmoyDx assay.
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